Evidence map›Paper›PMID 36685272›Full record

ArticleToxicology reports2023

Evaluation of

Yuta Fujii, Yuka Yoshino, Kazuhiro Chihara, Aya Nakae, Jun-Ichiro Enmi, Yoshichika Yoshioka, Izuru Miyawaki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yuta FujiiPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Yuka YoshinoPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Kazuhiro ChiharaPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Aya NakaeGraduate school of Frontier Biosciences, Osaka University, 1-3 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Jun-Ichiro EnmiGraduate school of Frontier Biosciences, Osaka University, 1-3 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Yoshichika YoshiokaGraduate school of Frontier Biosciences, Osaka University, 1-3 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Izuru MiyawakiPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Osaka University · JPNational Institute of Information and Communications Technology · JPSumitomo Dainippon Pharma (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are no specific and sensitive biomarkers for arteritis, and the occurrence of arteritis in nonclinical toxicological studies of a candidate drug makes development of the drug very difficult. However, we showed in a previous study that the high signal intensity region around the artery on magnetic resonance imaging (MRI) could be a candidate biomarker for detection of arteritis. The present study was conducted to clarify the details of midodrine hydrochloride (MH)-induced arteritis lesions and whether arteritis induced by a mechanism other than the vasodilatory effect, which was evaluated in a previous study, could be detected by MRI. MH is a selective peripherally acting alpha-1 adrenergic receptor agonist, known to induce arteritis due to its vasoconstrictor action, but there is not enough information about MH-induced arteritis. Based on the data obtained under multiple dosing conditions, MH was administered subcutaneously to each rat once daily for 2 days at a dose level of 40 mg/kg/day for MRI assessment. The mesenteric arteries were examined using

Indexed as

0.5% CMC, 0.5 w/v% carboxymethyl cellulose solutionArteritisBiomarkerDrugFLASH, fast low-angle shotFM, fenoldopam mesylateFOV, field of viewMagnetic resonance imagingMH, midodrine hydrochlorideMidodrine hydrochlorideMRI, magnetic resonance imagingPerivascular edemaRARE, rapid acquisition with relaxation enhancementTE, echo timeTR, repetition time

Identifiers

PMID36685272
PMCPMC9845950
OpenAlexW4313556483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.